Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

COMPARE FOR YOURSELF - 2012 to 2018 - IPIX $$$

AUGUST 31st 2012 - Closed at .63
September 31st 2012 - Closed at 1.00

In the 10-K released on 10/12/12 I found the below info. Here is link to 10-K (https://www.bamsec.com/filing/154823312000017?cik=1355250)

CASH ON HAND - $27,000
CTIX did not have any major Stock Purchase Agreements at the time! So no funds readily available.

OS as of SEPT 30th 2012 - - 93,124,151 (ABOUT 52 MILLION LESS than now)

They had ZERO CLINICAL trials - just pre-clinical work.

Some notes of accomplishments though:
Jan 2012 - Prurisol Patent Filed
March 2012 - BIDMC Agreement to test Keveterin
May 2012 - Jim Boeheim joined as advisor (lol) Jim is a good man but this was exciting at the time.
June 2012 - IND Meeting with FDA approved to seek section 505(b)(2)
June 2012 - IND approved by FDA to begin Phase 1 trial at Dana Farber and BIDMC for Keveterin
Sept 2012 - Selected Dr. Reddy's Lab to manufacturer P

COMPOUNDS OWNED BY CTIX in 2012: 8 TOTAL
Kevetrin
KM 133
KM 391
KM 277
KM 278
KM 362
KM-3174
KM-732

DESIGNATIONS: June 2012 for Prurisol - 505 (b)(2) Approach


_________________________________________________________________
FAST FORWARD ----- As of March 5th 2018 -----------

March 5th Close - .55
Total OS as of Jan 31st 2018 ----- 145,688,782 shares

Cash on hand: 3.2 Million

Financing in place: 25.6 MILLION available from ASPIRE
Financing in place: 75 Million Shelf Reg

Compounds Owned in 2018:
ADDITIONAL COMPOUNDS OWNED AFTER POLYMEDIX's acquisition: 18 TOTAL
**THIS INCLUDES PATENTS** It also included "SUBSTANTIAL EQUIPMENT ASSETS"
"We are very excited about instantly having a strong antibiotic franchise to complement our already robust pipeline that now contains 18 compounds"

ACCOMPLISHMENTS:
CLINICAL TRIALS: (Daubs summary)
1) PHASE I: A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
(Start: Oct 2012 - End: Feb 2016) SUCCESSFUL

2) PHASE 2B: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
(Start: Feb 2014 - END: Oct 2014) SUCCESSFUL
***Compared favorably to Daptomycin which is a blockbuster drug

3) PHASE I: Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
(Start: March 2014 - End: Oct 2014) SUCCESFUL

4) PHASE II: Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
(Start: Aug 2015 - End: May 2016) SUCCESSFUL

5) PHASE 2B: Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
(Start: Oct 2016 - End: Dec 2017) TOP LINE DATA IN WEEKS

6) PHASE 2: Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer (Brilacidin)
(Start: May 2015 - End: Dec 2017) SUCCESSFUL
MGMT COMMENT:

After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.

7) A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
(Start: Feb 2017 - End: Feb 2018) SUCCESSFUL

8) A Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease
(Start: June 2016 - End: June 2017) SUCCESSFUL

DESIGNATIONS FROM THE FDA:
Brilacidin -
1) QIDP Fast Track Designation ABSSSI - Dec 2014
2) Fast track Designation for OM - Nov 2015 (The company just released if the final OM results are on par with interim they will apply for BREAKTHROUGH DESIGNATION)
KEVETRIN -
3) Orphan Drug Designation for Ovarian Cancer - July 2015
4) Orphan Drug Designation for Retinoblastoma - Nov 2015
5) Rare Pediatric Disease Designation for Retinoblastoma - Nov 2015
(the case for Silver Spring-based United Therapeutics Corp., which sold a voucher for $350 million in 2015)
*Orphan Drug Designation for Pancreatic Cancer - Jan 2016
6) BREAKTHROUGH for B-OM has been applied for! Waiting on FDA (My opinion)

Approaching 20 CDA's with Big Pharm and other BIO's!

______________________________________________________

My summary - Are you kidding me? We have diluted 52 million shares since 2012 but accomplished more than most BIO TECH's will ever accomplish in that time. Look at the DESIGNATIONS - look at the CLINICAL TRIAL SUCCESSES - Look at the FINANCING available - look at the DRUGS COUNT we acquired - - - - etc...... And we are well below the share price then. WOW.

Also add to the fact that the market is at an all time HIGH! The BIO industry is secreting cash and hemorrhaging for deals.

IPIX defended itself against BS online blogs and BS lawsuits - they won with prejudice! They defended us the shareholders and won.

Stick to the facts all. This company and this Management team have done an amazing job. Leo will fight for all of us real shareholders to his death. The fun has not begun! We will rise and we will triumph.

I probably missed some good stuff - but figured I'd set the record straight here.

I also had a great very long conversation with an Exec at AbbVie - since he was taking on one of my employees and wanted to know more about him. I got the chance to pick his brain on BP deals and Share Price and etc.... Share Price DOES NOT MATTER - the drugs matter, the market for the drugs matter - the upcoming competition and drugs in that market matter - unmet need matters - FDA Designations matter - His advice from my explanation and I did not mention IPIX - he would be very stealth as MGMT - be quiet - entertain as many BP's as possible - and pick the best fit. Do not jump based off Share Price - UNLESS you had one drug - one indication - and your hands were tied and you had ONLY one or two interested (CDA's) and money running out. He said if you have more than one drug - and producing successful results in the clinic - and do not have unreal debt or terrible financing - SCIENCE WILL PAYOUT - in a big way! The convo was much more indepth - but figured I'd share from an Exec from a BP. And to end this long post - he said CDA's are a very big deal. It's not just paperwork and they are not filed every day for no reason. CDA's mean people are INTERESTED! Anyway that is a real life conversation.

We will have our day longs!